专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120149728A1 NOVEL FUMARATE SALTS OF A HISTAMINE H3 RECEPTOR ANTAGONIST 有权
标题翻译：一种组胺H3受体拮抗剂的新型富马酸钠
公开(公告)号：US20120149728A1
公开(公告)日：2012-06-14
申请号：US13314772
申请日：2011-12-08
申请人： Beverly C. LANGEVIN , Robert Allan FARR , Dinubhai H. SHAH , Daniel SHERER
发明人： Beverly C. LANGEVIN , Robert Allan FARR , Dinubhai H. SHAH , Daniel SHERER
IPC分类号： A61K31/4709 , A61P25/20 , A61P25/28 , A61P15/00 , A61P25/24 , A61P3/10 , A61P25/08 , A61P25/18 , A61P25/22 , C07D401/12 , A61P3/04
CPC分类号： C07D401/12
摘要： The disclosure relates to fumarate salts of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, to pharmaceutical compositions thereof, processes for making the same, and methods of use thereof.
摘要翻译：本公开涉及2-（环己基甲基）-N- {2 - [（2S）-1-甲基吡咯烷-2-基]乙基} -1,2,3,4-四氢异喹啉-7-磺酰胺的富马酸盐与药物其组合物，其制备方法及其使用方法。

2. 发明授权

US07642249B2 Dihydrogen phosphate salt of a prostaglandin D2 receptor antagonist 失效
标题翻译：前列腺素D2受体拮抗剂磷酸二氢盐
公开(公告)号：US07642249B2
公开(公告)日：2010-01-05
申请号：US12101282
申请日：2008-04-11
申请人： Beverly Langevin , Edward Orton , Daniel Sherer
发明人： Beverly Langevin , Edward Orton , Daniel Sherer
IPC分类号： C07D239/46 , A61K31/505
CPC分类号： C07D239/47
摘要： The present invention is directed to dihydrogen phosphate salt 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like, by administering to said patient a pharmaceutically effective amount of the compound of Formula (III).
摘要翻译：本发明涉及磷酸二氢盐2-（3- {6- [2-（2,4-二氯 - 苯基） - 乙基氨基] -2-甲氧基 - 嘧啶-4-基} - 苯基）-2-甲基（III）的丙酸，药物组合物，其包含药学上有效量的式（III）化合物和药学上可接受的载体; 以及治疗患有PGD2介导的病症的患者的方法，包括但不限于过敏性疾病（如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），系统性肥大细胞增多症，伴有全身性mast mast 细胞活化，过敏性休克，支气管收缩，支气管炎，荨麻疹，湿疹，伴有瘙痒的疾病（如特应性皮炎和荨麻疹），其次产生的疾病（如白内障，视网膜脱离，炎症，感染和睡眠障碍）伴有瘙痒的行为（例如搔抓和殴打），炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿性关节炎，胸膜炎，溃疡性结肠炎等，通过向所述患者施用药学有效量的式（III）的化合物。

3. 发明授权

US08664245B2 Fumarate salts of a histamine H3 receptor antagonist 有权
标题翻译：组胺H3受体拮抗剂的富马酸盐
公开(公告)号：US08664245B2
公开(公告)日：2014-03-04
申请号：US13314772
申请日：2011-12-08
申请人： Beverly C. Langevin , Robert Allan Farr , Dinubhai H. Shah , Daniel Sherer
发明人： Beverly C. Langevin , Robert Allan Farr , Dinubhai H. Shah , Daniel Sherer
IPC分类号： A01N43/42 , A61K31/47 , C07D217/00
CPC分类号： C07D401/12
摘要： The disclosure relates to fumarate salts of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, to pharmaceutical compositions thereof, processes for making the same, and methods of use thereof.
摘要翻译：本公开涉及2-（环己基甲基）-N- {2 - [（2S）-1-甲基吡咯烷-2-基]乙基} -1,2,3,4-四氢异喹啉-7-磺酰胺的富马酸盐与药物其组合物，其制备方法及其使用方法。

4. 发明申请

US20110257190A1 CRYSTALLINE FORMS 审中-公开
标题翻译：晶体形式
公开(公告)号：US20110257190A1
公开(公告)日：2011-10-20
申请号：US13151853
申请日：2011-06-02
申请人： Kenneth J. BORDEAU , Beverly C. LANGEVIN, II , George Everett LEE , Patricia LOGUE , Elizabeth SECORD , Daniel SHERER
发明人： Kenneth J. BORDEAU , Beverly C. LANGEVIN, II , George Everett LEE , Patricia LOGUE , Elizabeth SECORD , Daniel SHERER
IPC分类号： A61K31/4985 , A61K31/519 , A61P9/00 , A61P29/00 , C07D487/02 , A61P35/00
CPC分类号： C07D487/04 , A61K31/4985
摘要： The disclosure relates to crystalline forms of 2-[4-(7-ethyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenyl]-propan-2-ol, characterized by physico-chemical data described herein.
摘要翻译：本公开涉及2- [4-（7-乙基-5H-吡咯并[2,3-b]吡嗪-6-基） - 苯基] - 丙-2-醇的结晶形式，其特征在于所述的物理化学数据这里。

5. 发明申请

US20080194600A1 DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST 失效
标题翻译：前列腺素D2受体拮抗剂的二氢磷酸盐
公开(公告)号：US20080194600A1
公开(公告)日：2008-08-14
申请号：US12101282
申请日：2008-04-11
申请人： Beverly LANGEVIN , Edward ORTON , Daniel SHERER
发明人： Beverly LANGEVIN , Edward ORTON , Daniel SHERER
IPC分类号： A61K31/513 , C07D239/47
CPC分类号： C07D239/47
摘要： The present invention is directed to dihydrogen phosphate salt 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like, by administering to said patient a pharmaceutically effective amount of the compound of Formula (III).
摘要翻译：本发明涉及磷酸二氢盐2-（3- {6- [2-（2,4-二氯 - 苯基） - 乙基氨基] -2-甲氧基 - 嘧啶-4-基} - 苯基）-2-甲基（III）的丙酸，药物组合物，其包含药学上有效量的式（III）化合物和药学上可接受的载体; 以及治疗患有PGD2介导的病症的患者的方法，包括但不限于过敏性疾病（如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），系统性肥大细胞增多症，伴有全身性mast mast 细胞活化，过敏性休克，支气管收缩，支气管炎，荨麻疹，湿疹，伴有瘙痒的疾病（如特应性皮炎和荨麻疹），其次产生的疾病（如白内障，视网膜脱离，炎症，感染和睡眠障碍）伴有瘙痒的行为（例如搔抓和殴打），炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿性关节炎，胸膜炎，溃疡性结肠炎等，通过向所述患者施用药学有效量的式（III）的化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式